| Abstract: |
This review briefly summarizes literature noteworthy in the field of adult acute leukemia published during 1999. The relationship between specific cytogenetic abnormalities and response to treatment was explored within a clinical framework. In particular, detailed analyses of the abnormalities seen in acute promyelocytic leukemia were examined. Two case reports of special interest were published: one shed light on the role of histone deacetylase inhibitors in combination with all-trans retinoic acid, and the other, on the role of granulocyte colony-stimulating factor in this disease. The clinical activity of arsenic was also reported and its mechanism of action explored. In acute lymphoblastic leukemia, attention was focused on occult translocations, and the importance of minimal residual disease was again emphasized. Lastly, results of early clinical trials using an anti-CD 19 antibody were reported, with provocative results. (C) 2000 Lippincott Williams and Wilkins, Inc. |
| Keywords: |
adolescent; adult; child; human tissue; treatment outcome; middle aged; leukemia; unclassified drug; human cell; review; combined modality therapy; cytarabine; cancer immunotherapy; etoposide; antineoplastic combined chemotherapy protocols; neoplasm proteins; cytogenetics; drug resistance, neoplasm; drug design; acute lymphoblastic leukemia; leukemia, promyelocytic, acute; antibodies, monoclonal; acute leukemia; drug mechanism; infant; neoplasm, residual; randomized controlled trials; leukemia, myeloid; dna, neoplasm; daunorubicin; acute myeloblastic leukemia; chromosome aberrations; bone marrow transplantation; granulocyte colony stimulating factor; retinoic acid; antigens, cd19; tioguanine; clinical trials; multidrug resistance; acute disease; drug resistance, multiple; tretinoin; multicenter studies; histone acetyltransferase; leukemia, lymphocytic, acute; cd19 antibody; humans; prognosis; human; priority journal; hd 37; histone acetyltransferase inhibitor
|
